Home
Home

M&A

Allergan and MAP: Pharma Buyout With a 60% Premium

Allergan and MAP: Pharma Buyout With a 60% Premium
Motley Fool

Shire to Forest on Deal List for AstraZeneca: Real M&A

Shire to Forest on Deal List for AstraZeneca: Real M&A
Bloomberg

GSK, others weigh $3-4 billion deal for Brazilian drugmaker: sources

GSK, others weigh $3-4 billion deal for Brazilian drugmaker: sources
Reuters

Reckitt in $482 mln deal to sell Bristol drugs in LatAm

Reckitt in $482 mln deal to sell Bristol drugs in LatAm
Reuters

Endo Seen Boosted by Fidelity-Favored Sale: Real M&A

Endo Seen Boosted by Fidelity-Favored Sale: Real M&A
Bloomberg

China Biotech In Review: Cardinal Health Uses M&A To Add Drug Distribution Reach

China Biotech In Review: Cardinal Health Uses M&A To Add Drug Distribution Reach
Seeking Alpha

Gilead Sciences completes acquisition of YM BioSciences

Gilead Sciences completes acquisition of YM BioSciences
Yahoo/PR Newswire

India's Sun Pharma ends deal to take over Israeli unit Taro

India's Sun Pharma ends deal to take over Israeli unit Taro
Reuters

Tranzyme to explore sale of company

Tranzyme to explore sale of company
Reuters

Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments

Elan seeks acquisitions after $3.25 bn Biogen Idec deal, rival Bayer eyed on MS treatments
Financial Express